PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/15/2018
Start Date:February 2010
End Date:December 2018

Use our guide to learn which trials are right for you!

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

The purpose of this trial is to evaluate 2-year disease-free survival in this patient
population treated with single agent cisplatin and patients treated with cisplatin in
combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability
of this treatment in patients with residual disease following preoperative chemotherapy will
also be observed and characterized.

OUTLINE: This is a multi-center study.

Safety Run-in will be for the first 12 patients on study only (6 in cohort 1 and 6 in cohort
2). Patients in the safety run will be included in the efficacy analysis on intent to treat
basis:

Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib 16-30 mg IV D 1,2,3 every 3
weeks x 4 cycles

If cycle 1 is well tolerated, the dose of Rucaparib will be escalated from 16 mg to 24 mg for
subsequent cycles in the cohort 1, and 24 mg to 30 mg in the cohort 2.

If ≤ 1 of 6 patients in cohort 1 experiences DLT, cohort 2 will commence. If 2 or more of 6
patients in cohort 1 experience DLT, the study will be suspended and an amendment to explore
lower doses will be considered.

If ≤ 1 of 6 patients in cohort 2 experiences DLT, the randomized portion of the study will
commence. If 2 or more of 6 patients experience DLT, the study will be suspended and an
amendment to proceed with the randomized portion at the cohort 2 dose (24 mg) will be
considered.

During the randomized portion of the study, patients will be randomized to either Arm A or
Arm B.

Stratification factors:

- Anthracycline vs. not

- Residual LN involvement vs. No Residual LN involvement

Arm A (Cisplatin Monotherapy) Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles

Arm B (Combination Therapy) Cisplatin 75 mg/m2 IV D1 every 3 weeks x 4 cycles; Rucaparib
16-30 mg IV D1,2,3 every 3 weeks x 4 cycles

Rucaparib maintenance 30 mg IV weekly x 24 weeks

ECOG Performance Status 0-1

Life Expectancy: Not Specified

Hematopoietic:

- Hemoglobin (Hgb) > 9.0 g/dL

- Platelets > 100 K/ mm3

- Absolute neutrophil count (ANC) > 1.5 K/mm3

Hepatic:

- Bilirubin < upper limit of normal (except in patients with documented Gilbert's disease,
who must have a total bilirubin < 3.0 mg/dL)

- Aspartate aminotransferase (AST, SGOT) < 2.5 x ULN

- Alanine aminotransferase (ALT, SGPT) < 2.5 x ULN

Renal:

- Calculated creatinine clearance of > 50 cc/min using the Cockcroft-Gault formula

Cardiovascular:

- Left ventricular ejection fraction within normal limits.

- Patients with an unstable angina or myocardial infarction within 12 months of study
entry are excluded.

- No clinically significant arrhythmia or baseline ECG abnormalities in the opinion of the
treating investigator.

Inclusion Criteria:

- Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-)
invasive breast cancer, stage I-III at diagnosis (AJCC 6th edition) based on initial
evaluation by clinical examination and/or breast imaging. NOTE: Patients with ER+
and/or PR+ may enroll ONLY if they are known carriers of a deleterious mutation in
BRCA1 or BRCA2. Patients with HER2+ tumors may not enroll regardless of BRCA status.

- Must have completed preoperative (neoadjuvant) chemotherapy. NOTE: Acceptable
preoperative regimens include an anthracycline or a taxane, or both. Patients may NOT
have received cisplatin as part of their neoadjuvant therapy regimen. Patients who
received preoperative therapy as part of a clinical trial may enroll. No adjuvant
chemotherapy after surgery other than that specified in this protocol is allowed.
Adjuvant bisphosphonate use is allowed.

- Must have completed definitive resection of primary tumor. The last surgery for breast
cancer must have been completed at least 14 days prior to registration for protocol
therapy.

- Must have significant residual invasive disease at the time of definitive surgery
following preoperative chemotherapy. Significant residual disease is defined at least
one of the following:

- Miller-Payne response in the breast of 0-25.

- Residual Cancer Burden (RBC) classification II or III6

- Residual carcinoma in one or more regional lymph nodes that would meet AJCC 6th
edition criteria for N1 - N3 disease.

- Alternatively, if Miller-Payne or RCB grading is not available, the patient will
be eligible if the pathology report indicates that the area of residual invasive
disease in the breast measures at least 2 cm following preoperative therapy. The
presence of DCIS without invasion does not qualify as residual disease in the
breast.

- Whole breast radiotherapy is required for patients who underwent breast conserving
therapy, including lumpectomy or partial mastectomy. Patients receiving adjuvant
radiation therapy must have completed radiotherapy at least 14 days prior to
registration for protocol therapy.

- Written informed consent and HIPAA authorization for release of personal health
information.

- Age > 18 years at the time of consent.

- Must consent to allow submission of archived tumor tissue sample from definitive
surgery.

- Must consent to collection of blood samples for PK analysis.

- Women of childbearing potential and males must be willing to use an effective method
of contraception from the time consent is signed until 4 weeks after treatment
discontinuation.

- Women of childbearing potential must have a negative pregnancy test within 14 days
prior to registration for protocol therapy.

- Women must not be breastfeeding.

Exclusion Criteria:

- No stage IV (metastatic) disease, however no specific staging studies are required in
the absence of symptoms or physical exam findings that would suggest distant disease.

- No treatment with any investigational agent within 30 days prior to registration for
protocol therapy.

- No history of chronic hepatitis B or C

- No clinically significant infections as judged by the treating investigator.
We found this trial at
27
sites
100 N Humphreys Blvd
Memphis, Tennessee 38120
(901) 683-0055
The West Clinic, PC Hello and welcome to our office. Although it is our pleasure...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
220 S Palisade Dr # 204
Santa Maria, California 93454
?
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Asheville, North Carolina 28816
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Cherry Hill, New Jersey 08003
?
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Cleveland, Ohio 44106
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Fort Wayne, Indiana 46815
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Fullerton, California 92835
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
Harrisburg, Pennsylvania 17110
?
mi
from
Harrisburg, PA
Click here to add this to my saved trials
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
Indianapolis, Indiana 46256
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148
702.952.1251
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1475 NW 12th Ave
Miami, Florida 33136
(305) 243-1000
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mount Holly, New Jersey 08060
?
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Munster, Indiana 46321
?
mi
from
Munster, IN
Click here to add this to my saved trials
5900 Lake Wright Dr
Norfolk, Virginia 23502
(757) 466-8683
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Portland, Oregon 97227
?
mi
from
Portland, OR
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Sellersville, PA
Click here to add this to my saved trials
615 N Michigan Street
South Bend, Indiana 46601
(574) 647-7370
Northern Indiana Cancer Research Consortium The Northern Indiana Cancer Research Consortium (NICRC) is comprised of...
?
mi
from
South Bend, IN
Click here to add this to my saved trials
Vineland, New Jersey 08360
?
mi
from
Vineland, NJ
Click here to add this to my saved trials
Wyoming, Michigan 49519
?
mi
from
Wyoming, MI
Click here to add this to my saved trials